PFE Mar 2025 37.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:32PM EDT. Market open.
| Previous close | 0.1600 |
| Open | 0.1600 |
| Bid | 0.1400 |
| Ask | 0.1700 |
| Strike | 37.50 |
| Expiry date | 2025-03-21 |
| Day's range | 0.1500 - 0.1600 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.95k |
Investor's Business DailyWhy Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.
ZacksPfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
Simply Wall St.The past three years for Pfizer (NYSE:PFE) investors has not been profitable
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
© 2024 Yahoo. All rights reserved.